During the past decade, Emergency Institute for Cardiovascular Diseases conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Emergency Institute for Cardiovascular Diseases" are "Atrial Fibrillation" (1 trials), "Heart Failure" (1 trials) and "Prevention of Stroke or Systemic Embolism" (1 trials). Many other conditions were trialed in "Emergency Institute for Cardiovascular Diseases" in a lesser frequency.

Most popular intervention types in "Emergency Institute for Cardiovascular Diseases" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials), "Asundexian matching placebo" (1 trials) and "Finerenone (BAY94-8862)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Emergency Institute for Cardiovascular Diseases" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Emergency Institute for Cardiovascular Diseases". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Emergency Institute for Cardiovascular Diseases, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Emergency Institute for Cardiovascular Diseases, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".